Análisis de la acción AtaiBeckley Inc (ATAI)ATAIAtaiBeckley Inc

AtaiBeckley Inc is a clinical-stage biotechnology company focused on developing rapid-acting, durable and convenient mental health treatments. The Company’s pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 (R-MDMA HCI) for social anxiety disorder. The Company is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for opioid use disorder and TRD. BPL-003 is a proprietary synthetic intranasal formulation of mebufotenin benzoate being developed as a potential treatment for people living with TRD. VLS-01 is a proprietary oral transmucosal film formulation of N,N-Dimethyltryptamine (DMT) being developed as a potential treatment for people living with TRD. EMP-01 is an oral formulation of R-MDMA, being developed as a potential treatment for people living with social anxiety disorder. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

ATAI Life Sciences NV is not a good buy right now, as the current price of $7.29 is above the downgraded analyst price targets of $7.50 and $8. The stock has experienced a significant decline in analyst ratings due to the pending acquisition by Eli Lilly, which offers a cash payment of $6.75 per share plus contingent payments. Furthermore, the RSI is at 40.989, indicating a lack of momentum for a potential upward move, and the recent 5-day change is down by 1.22%.